First Time Loading...

Affimed NV
NASDAQ:AFMD

Watchlist Manager
Affimed NV Logo
Affimed NV
NASDAQ:AFMD
Watchlist
Price: 5.15 USD -0.19% Market Closed
Updated: May 22, 2024

Intrinsic Value

AFMD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Affimed NV engages in the discovery and development of cancer immunotherapies. [ Read More ]

The intrinsic value of one AFMD stock under the Base Case scenario is 8.28 USD. Compared to the current market price of 5.15 USD, Affimed NV is Undervalued by 38%.

Key Points:
AFMD Intrinsic Value
Base Case
8.28 USD
Undervaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Affimed NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AFMD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Affimed NV

Provide an overview of the primary business activities
of Affimed NV.

What unique competitive advantages
does Affimed NV hold over its rivals?

What risks and challenges
does Affimed NV face in the near future?

Summarize the latest earnings call
of Affimed NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Affimed NV.

Provide P/S
for Affimed NV.

Provide P/E
for Affimed NV.

Provide P/OCF
for Affimed NV.

Provide P/FCFE
for Affimed NV.

Provide P/B
for Affimed NV.

Provide EV/S
for Affimed NV.

Provide EV/GP
for Affimed NV.

Provide EV/EBITDA
for Affimed NV.

Provide EV/EBIT
for Affimed NV.

Provide EV/OCF
for Affimed NV.

Provide EV/FCFF
for Affimed NV.

Provide EV/IC
for Affimed NV.

Show me price targets
for Affimed NV made by professional analysts.

What are the Revenue projections
for Affimed NV?

How accurate were the past Revenue estimates
for Affimed NV?

What are the Net Income projections
for Affimed NV?

How accurate were the past Net Income estimates
for Affimed NV?

What are the EPS projections
for Affimed NV?

How accurate were the past EPS estimates
for Affimed NV?

What are the EBIT projections
for Affimed NV?

How accurate were the past EBIT estimates
for Affimed NV?

Compare the revenue forecasts
for Affimed NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Affimed NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Affimed NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Affimed NV compared to its peers.

Compare the P/E ratios
of Affimed NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Affimed NV with its peers.

Analyze the financial leverage
of Affimed NV compared to its main competitors.

Show all profitability ratios
for Affimed NV.

Provide ROE
for Affimed NV.

Provide ROA
for Affimed NV.

Provide ROIC
for Affimed NV.

Provide ROCE
for Affimed NV.

Provide Gross Margin
for Affimed NV.

Provide Operating Margin
for Affimed NV.

Provide Net Margin
for Affimed NV.

Provide FCF Margin
for Affimed NV.

Show all solvency ratios
for Affimed NV.

Provide D/E Ratio
for Affimed NV.

Provide D/A Ratio
for Affimed NV.

Provide Interest Coverage Ratio
for Affimed NV.

Provide Altman Z-Score Ratio
for Affimed NV.

Provide Quick Ratio
for Affimed NV.

Provide Current Ratio
for Affimed NV.

Provide Cash Ratio
for Affimed NV.

What is the historical Revenue growth
over the last 5 years for Affimed NV?

What is the historical Net Income growth
over the last 5 years for Affimed NV?

What is the current Free Cash Flow
of Affimed NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Affimed NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Affimed NV

Current Assets 84.2m
Cash & Short-Term Investments 72m
Receivables 5.3m
Other Current Assets 6.8m
Non-Current Assets 13m
PP&E 12.9m
Intangibles 25k
Current Liabilities 25.9m
Accounts Payable 18.9m
Other Current Liabilities 7m
Non-Current Liabilities 13.4m
Long-Term Debt 13m
Other Non-Current Liabilities 464k
Efficiency

Earnings Waterfall
Affimed NV

Revenue
8.3m EUR
Cost of Revenue
-1.3m EUR
Gross Profit
6.9m EUR
Operating Expenses
-114.5m EUR
Operating Income
-107.6m EUR
Other Expenses
1.7m EUR
Net Income
-105.9m EUR

Free Cash Flow Analysis
Affimed NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

AFMD Profitability Score
Profitability Due Diligence

Affimed NV's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROIC
ROIC is Increasing
Exceptional Revenue Growth Forecast
36/100
Profitability
Score

Affimed NV's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

AFMD Solvency Score
Solvency Due Diligence

Affimed NV's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
50/100
Solvency
Score

Affimed NV's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AFMD Price Targets Summary
Affimed NV

Wall Street analysts forecast AFMD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AFMD is 23.31 USD with a low forecast of 5.05 USD and a high forecast of 63 USD.

Lowest
Price Target
5.05 USD
2% Downside
Average
Price Target
23.31 USD
353% Upside
Highest
Price Target
63 USD
1 123% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Affimed NV

Shareholder Return

AFMD Price
Affimed NV

1M 1M
+3%
6M 6M
+3%
1Y 1Y
-52%
3Y 3Y
-94%
5Y 5Y
-83%
10Y 10Y
-91%
Annual Price Range
5.15
52w Low
3.173
52w High
10.7
Price Metrics
Average Annual Return 7.27%
Standard Deviation of Annual Returns 87.12%
Max Drawdown -97%
Shares Statistics
Market Capitalization 76.9m USD
Shares Outstanding 14 939 916
Percentage of Shares Shorted 1.43%

AFMD Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Affimed NV Logo
Affimed NV

Country

Germany

Industry

Biotechnology

Market Cap

76.9m USD

Dividend Yield

0%

Description

Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Contact

BADEN-WUERTTEMBERG
Heidelberg
Im Neuenheimer Feld 582
+49622165307.0
https://www.affimed.com/

IPO

2014-09-12

Employees

187

Officers

Interim CEO, Chief Medical Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
MD, COO & Member of Management Board
Dr. Wolfgang Fischer Ph.D.
Chief Business Officer & Member of Management Board
Ms. Denise Mueller
Founder & Consultant
Prof. Melvyn Little
Head of Finance & Administration
Mr. Michael Wolf
Head of Investor Relations & Director of Investor Relations
Mr. Alexander Fudukidis
Show More
Vice President of Marketing & Communications
Mary Beth Sandin
Show Less

See Also

Discover More
What is the Intrinsic Value of one AFMD stock?

The intrinsic value of one AFMD stock under the Base Case scenario is 8.28 USD.

Is AFMD stock undervalued or overvalued?

Compared to the current market price of 5.15 USD, Affimed NV is Undervalued by 38%.